This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://localhost/temp/predkladatel/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F14%3A33148908%21RIV15-MSM-15110___/
n5http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n8http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n15http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F14%3A33148908%21RIV15-MSM-15110___
rdf:type
skos:Concept n5:Vysledek
rdfs:seeAlso
http://nobleresearch.org/Journals/JCRT/Volume2/2052-4994-2014-8.aspx
dcterms:description
GastroIntestional stromal tumours (GISTs), the most frequent sarcoma in the gastro-intestinal (GI) tract, are highly resistant to conventional chemotherapy and radiotherapy. These tumours have activating mutations in two closely related genes, KIT (75-80%) or/and PDGFRA (5-10%). Targeting these mutated activated proteins with imatinib mesylate has proven efficient in the treatment of GISTs. The median survival after diagnosis of GIST increased from 1.5 to 4.8 years with imatinib treatment. However, resistance to imatinib eventually develops and new-targeted therapies are needed. This paper reviews the medical, clinical and pathological aspects of GISTs based on latest research in human cell lines and animal models. GastroIntestional stromal tumours (GISTs), the most frequent sarcoma in the gastro-intestinal (GI) tract, are highly resistant to conventional chemotherapy and radiotherapy. These tumours have activating mutations in two closely related genes, KIT (75-80%) or/and PDGFRA (5-10%). Targeting these mutated activated proteins with imatinib mesylate has proven efficient in the treatment of GISTs. The median survival after diagnosis of GIST increased from 1.5 to 4.8 years with imatinib treatment. However, resistance to imatinib eventually develops and new-targeted therapies are needed. This paper reviews the medical, clinical and pathological aspects of GISTs based on latest research in human cell lines and animal models.
dcterms:title
Gastrointestinal stromal tumour: From the clinic to the molecules Gastrointestinal stromal tumour: From the clinic to the molecules
skos:prefLabel
Gastrointestinal stromal tumour: From the clinic to the molecules Gastrointestinal stromal tumour: From the clinic to the molecules
skos:notation
RIV/61989592:15110/14:33148908!RIV15-MSM-15110___
n4:aktivita
n14:I
n4:aktivity
I
n4:cisloPeriodika
3
n4:dodaniDat
n15:2015
n4:domaciTvurceVysledku
n11:3131912 n11:6974899
n4:druhVysledku
n12:J
n4:duvernostUdaju
n17:S
n4:entitaPredkladatele
n19:predkladatel
n4:idSjednocenehoVysledku
17950
n4:idVysledku
RIV/61989592:15110/14:33148908
n4:jazykVysledku
n9:eng
n4:klicovaSlova
imatinib mesylate; activating mutation; platelet-derived growth factor receptor alpha; KIT; smooth muscle cells; interstitial cells of cajal; gastrointestinal stromal tumours
n4:klicoveSlovo
n10:KIT n10:gastrointestinal%20stromal%20tumours n10:interstitial%20cells%20of%20cajal n10:imatinib%20mesylate n10:platelet-derived%20growth%20factor%20receptor%20alpha n10:smooth%20muscle%20cells n10:activating%20mutation
n4:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n4:kontrolniKodProRIV
[26F38B3AD0B9]
n4:nazevZdroje
Journal of Cancer Research & Therapy
n4:obor
n16:FE
n4:pocetDomacichTvurcuVysledku
2
n4:pocetTvurcuVysledku
4
n4:rokUplatneniVysledku
n15:2014
n4:svazekPeriodika
2
n4:tvurceVysledku
Barbara P, De Santa Hapková, Ilona Florence, Bernex Veselý, Jaroslav
s:issn
2052-4994
s:numberOfPages
14
n8:doi
10.14312/2052-4994.2014-8
n18:organizacniJednotka
15110